ArticleJournal of neuro-oncology2025
Perioperative leukocyte-plateletcrit shift as a prognostic signature in glioblastoma.
Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeCirculating inflammatory indices derived from routine blood counts may offer pragmatic prognostic information in glioblastoma (GB), yet the prognostic role of plateletcrit (PCT) and of peri-treatment dynamics in leukocyte-platelet coupling remains underexplored.
methodsWe retrospectively studied 95 adults with histologically confirmed GB (48 men, 47 women; median age 64.5 years) treated adjuvantly with radiotherapy and chemotherapy with complete blood counts obtained at four windows: pre-operative, post-operative, pre-adjuvant, and post-adjuvant. From leukocytes, platelets (PLT), plateletcrit (PCT), and mean platelet volume (MPV) we derived all within-timepoint ratios and inter-timepoint differences (Δ). Overall survival (OS) in days was modeled using Cox proportional hazards (per + 1 SD), with Benjamini-Hochberg false-discovery summaries; a multivariable model adjusted for age, sex, extent of resection, radiotherapy, concomitant temozolomide (TMZ), and number of adjuvant TMZ cycles was calculated.
resultsMedian overall survival (OS) was 406 days, with 80 deaths. In univariate models, dynamic indices predominated: the post-operative rise in leukocytes relative to plateletcrit (Δ post-op - pre-op leu/PCT) showed the strongest adverse association (HR 1.60, 95% CI 1.22-2.10; p = 0.0007; BH-FDR q = 0.09), with concordant signals for Δ leu/PLT (HR 1.43, 95% CI 1.14-1.79; p = 0.002) and a protective inverse for Δ PCT/leu (HR 0.66, 95% CI 0.50-0.87; p = 0.003). Cross-sectionally, higher post-operative leu/PCT and leu/PLT and higher post-adjuvant leukocytes and leu/MPV were adverse (all p < 0.05). In the multivariable model adjusting for age, sex, extent of resection, radiotherapy, concomitant temozolomide (TMZ), and number of adjuvant TMZ cycles, Δ leu/PCT remained independently associated with worse OS (HR 1.62, 95% CI 1.04-2.52; p = 0.031), while concomitant TMZ (HR 0.18, 95% CI 0.05-0.68; p = 0.012) and greater adjuvant TMZ exposure (per + 1 SD; HR 0.48, 95% CI 0.29-0.78; p = 0.003) were protective.
conclusionsDynamic leukocyte-platelet coupling-especially Δ (post-op - pre-op) leu/PCT-provides independent prognostic information beyond standard covariates. CBC-based trajectories are low-cost and scalable and warrant prospective validation. Interpretation is limited by the absence of systematic MGMT methylation data and requires external validation and comparison with other prognostic scoring systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.